---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-25-000050"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2025-06-03T23:59:59+00:00"
generated_at: "2026-05-20T01:12:42.783861+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kiora grants Senju exclusive option for KIO-301 in Asia; $1.25M upfront, up to $110M milestones plus royalties

## Summary
- Immediate $1.25M option payment; if exercised, mid-single-digit million upfront and up to $110M in development, regulatory, and commercial milestones.
- Tiered royalties from high single-digit to high teen percent on net sales; territory covers Japan, China, and other key Asian countries.
- Option exercisable after topline data from ongoing ABACUS-2 Phase 2 trial; Senju to collaborate with Théa, Kiora's ex-Asia partner.
- Combined deal value with Théa (2024) and Senju exceeds $400M plus royalties; cash runway extended into late 2027.
- KIO-301 is a molecular photoswitch for retinitis pigmentosa and other inherited retinal diseases, currently in Phase 2.

## SEC filing metadata
- accession: 0001372514-25-000050
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2025-06-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251425000050/0001372514-25-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251425000050/kprx-20250530.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-25-000050
- JSON: https://secwatch.observer/filing/0001372514-25-000050.json
- Plain text: https://secwatch.observer/filing/0001372514-25-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.